IQVIA™ Real-World Insights Bibliography

FINANCIAL IMPACT OF INTRODUCING SC TRASTUZUMAB (HERCEPTIN) VERSUS CURRENTLY USED IV TRASTUZUMAB (HERCEPTIN) ON THE BUDGETS OF DIFFERENT HOSPITALS ACROSS KINGDOM OF SAUDI ARABIA (KSA)
Author(s): AL-Tweigeri T1, Al-Shihri A2, Abdelhafeez N2, Ali A3, Zekri J4, Al Mansour M5, Al-gahmi A6, Ansari J7, Elbahaei A8, F Husseiny8, Awad N9, Safwat M9, Goyal R10
Affiliations(s): 1King Faisal Specialist Hospital, Riyadh, Kingdom of Saudi Arabia (KSA), 2King Fahad National Guard Hospital, Riyadh, Saudi Arabia and 9QuintilesIMS, Dubai; 10QuintilesIMS, India
Publication(s):  ISPOR 20th European conference, 4-8 November, 2017
Document Type(s): Abstract,
Countries: Saudi Arabia,
Click here for the abstract
C:
Y:
Oncology,
2017
  L:
A:
English
Budget impact, Clinical setting: hospital, Survey research,
  Add to report
 
 
Direct medical costs of diabetes-related complications in Saudi Arabia
Author(s): 1. Hnoosh A IMS Health, HEOR, London, UK 2. Vega-Hernández G IMS Health, HEOR, London, UK 3. Jugrin A IMS Health, HEOR, London, UK 4. Todorova L Novo Nordisk International Operations, Zürich, Switzerland
Affiliations(s): IMS Health HEOR and Novo Nordisk International Operations, Zurich
Publication(s):  ISPOR 17th Annual International Meeting, Washington, USA
Document Type(s): Conference, Poster,
Countries: Saudi Arabia,
C:
Y:
Diabetes,
2012
  L:
A:
English
Literature Review,
  Add to report
 
 
Type II diabetes cost of illness study
Author(s): S. Babineaux1, W. Fakhoury2, A. McDonell3, R. Kotchie3, M. Ali4.
Affiliations(s): 1Eli Lilly and Company, Global Health Outcomes, Indianapolis IN, USA. 2Eli Lilly and Company, Global Health Outcomes, Erl Wood, United Kingdom. 3IMS Health, UK, London, United Kingdom. 4IMS Health, Saudi Arabia, Riyadh, Saudi Arabia.
Publication(s):  World Diabetes Congress December 2011, Dubai, UAE
Document Type(s): Conference, Poster,
Countries: Saudi Arabia,
C:
Y:
Diabetes,
2011
  L:
A:
English
Literature Review,
  Add to report
 
 
Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia
Author(s): Mohammed Ali 1 , Jeremy White 2 , Chen-Hui Lee 2 , James L Palmer 3 , Jayne Smith-Palmer 3 , Walid Fakhoury 4 , William J Valentine 3
Affiliations(s): 1 IMS Health, Riyadh, Saudi Arabia 2 Novo Nordisk International Operations A/S, Zurich, Switzerland 3 IMS Health, Basel, Switzerland 4 IMS Health, London, UK
Publication(s):  Journal of Medical Economics 2008; 11: 651–670
Document Type(s): Abstract,
Countries: Saudi Arabia,
C:
Y:
Diabetes,
2008
  L:
A:
English
Cost analysis,
  Add to report